Target Name: ILF3
NCBI ID: G3609
Other Name(s): NFAR-1 | NF90c | translational control protein 80 | MPHOSPH4 | MMP4 | NFAR90 | NF90b | M phase phosphoprotein 4, nuclear factor associated with DS RNA | Interleukin enhancer binding factor 3, transcript variant 5 | NF110 | NF90ctv | ILF3_HUMAN | dsRNA binding protein NFAR-2/MPP4 | TCP80 | interleukin enhancer binding factor 3, 90kD | ILF3 variant 4 | Interleukin enhancer binding factor 3, transcript variant 4 | interleukin enhancer binding factor 3, 90kDa | Interleukin enhancer-binding factor 3 (isoform d) | MPP4 | nuclear factor associated with dsRNA | DRBF | NF90a | NF110b | Nuclear factor associated with dsRNA | Interleukin enhancer binding factor 3 | interleukin enhancer binding factor 3 | TCP110 | CBTF | ILF3 variant 5 | NF90 | DsRNA binding protein NFAR-2/MPP4 | Interleukin enhancer-binding factor 3 (isoform e) | NFAR | NFAR-2 | Nuclear factor of activated T-cells 90 kDa | NFAR110 | M-phase phosphoprotein 4 | Translational control protein 80 | Interleukin enhancer-binding factor 3 | nuclear factor of activated T-cells, 90 kD | Nuclear factor of activated T-cells, 90 kD | MPP4110 | Double-stranded RNA-binding protein, 76 kD | Double-stranded RNA-binding protein 76 | double-stranded RNA-binding protein, 76 kD | nuclear factor of activated T-cells 90 kDa | NFAR2 | DRBP76 | NF-AT-90 | nuclear factor of activated T-cells 110 kDa

NFAT and IL-3: A Study of Immune Regulation and Potential Drug Targets

The interleukin-3 (IL-3) protein is a key regulator of immune responses and has been implicated in a variety of diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. The nuclear factor of activating T cells (NFAT) is a transcription factor that regulates the expression of IL-3. NFAT has three functional subunits: NFAT1, NFAT2, and NFAT3. The nuclear factor of activating T cells (NFAT) is a transcription factor that regulates the expression of IL-3. NFAT has three functional subunits: NFAT1, NFAT2, and NFAT3. The study of NFAT and its subunits has been an active area of research in recent years, with a focus on understanding its role in disease and developing new treatments.

IL-3 as a drug target

IL-3 has been identified as a potential drug target for a variety of diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. IL-3 is a key regulator of immune responses and has been shown to play a role in the development and progression of autoimmune diseases. For example, studies have shown that IL-3 is involved in the regulation of T cell development and activation, and that its levels are elevated in individuals with autoimmune disorders.

In addition to its role in immune regulation, IL-3 has also been shown to play a role in the development and progression of cancer. For example, studies have shown that IL-3 is involved in the regulation of cell survival and that its levels are elevated in cancer cells. This suggests that IL-3 may be a useful target for cancer treatments.

IL-3 has also been shown to be involved in the development and progression of neurodegenerative diseases. For example, studies have shown that IL-3 is involved in the regulation of neuron survival and that its levels are elevated in individuals with neurodegenerative diseases. This suggests that IL-3 may be a useful target for neurodegenerative disease treatments.

The potential benefits of targeting IL-3

Targeting IL-3 as a drug target has the potential to treat a variety of diseases. For example, IL-3 has been shown to be involved in the regulation of immune responses, and treatments that target IL-3 have been shown to be effective in treating autoimmune disorders. Additionally, IL-3 has been shown to play a role in the development and progression of cancer, and treatments that target IL-3 have been shown to be effective in treating cancer. Finally, IL-3 has also been shown to be involved in the development and progression of neurodegenerative diseases, and treatments that target IL-3 have been shown to be effective in treating neurodegenerative diseases.

IL-3 as a biomarker

IL-3 has also been used as a biomarker for a variety of diseases. For example, studies have shown that IL-3 levels are elevated in individuals with autoimmune disorders, and that treatments that target IL-3 have been shown to be effective in treating these disorders. Additionally, IL-3 has been shown to be involved in the regulation of cell survival, and biomarkers that measure cell survival have been used to diagnose and monitor a variety of diseases, including cancer.

IL-3 as a drug

In addition to its potential as a biomarker, IL-3 has also been identified as a potential drug target for a variety of diseases. For example, studies have shown that IL-3 is involved in the regulation of immune responses, and that treatments that target IL-3 have been shown to be effective in treating autoimmune disorders. Additionally, IL-3 has been shown to play a role in the development and progression of cancer, and treatments that target IL-3 have been shown to be effective in treating cancer. Finally, IL-3 has also been shown to be involved in the development and progression of neurodegenerative diseases, and treatments that target IL-3 have been shown to be effective in treating neurodegenerative diseases.

Conclusion

In conclusion, IL-3 is a protein that plays

Protein Name: Interleukin Enhancer Binding Factor 3

Functions: RNA-binding protein that plays an essential role in the biogenesis of circular RNAs (circRNAs) which are produced by back-splicing circularization of pre-mRNAs. Within the nucleus, promotes circRNAs processing by stabilizing the regulatory elements residing in the flanking introns of the circularized exons. Plays thereby a role in the back-splicing of a subset of circRNAs (PubMed:28625552). As a consequence, participates in a wide range of transcriptional and post-transcriptional processes. Binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs (PubMed:14731398). Upon viral infection, ILF3 accumulates in the cytoplasm and participates in the innate antiviral response (PubMed:21123651, PubMed:34110282). Mechanistically, ILF3 becomes phosphorylated and activated by the double-stranded RNA-activated protein kinase/PKR which releases ILF3 from cellular mature circRNAs. In turn, unbound ILF3 molecules are able to interact with and thus inhibit viral mRNAs (PubMed:21123651, PubMed:28625552)

More Common Targets

ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3 | IMP4 | IMPA1 | IMPA1P1 | IMPA2 | IMPACT | IMPDH1 | IMPDH1P10 | IMPDH1P6 | IMPDH2 | IMPG1 | IMPG2 | INA | INAFM1 | INAFM2 | INAVA | INCA1 | INCENP | INE1 | INE2 | INF2 | ING1 | ING2 | ING2-DT | ING3 | ING4 | ING5 | INGX | INHA | INHBA | INHBA-AS1 | INHBB | INHBC | INHBE | INHCAP | Inhibitor of Apoptosis Proteins (IAPs) | Inhibitory kappaB Kinase (IKK) | INIP | INKA1 | INKA2 | INKA2-AS1 | INMT | INMT-MINDY4 | Innate Repair Receptor (IRR) | INO80 | INO80 complex | INO80B | INO80B-WBP1 | INO80C | INO80D | INO80E | Inositol 1,4,5-Trisphosphate Receptor (InsP3R) | Inositol hexakisphosphate kinase | Inositol Monophosphatase | INPP1 | INPP4A | INPP4B | INPP5A | INPP5B | INPP5D | INPP5E | INPP5F | INPP5J | INPP5K | INPPL1 | INS | INS-IGF2 | INSC | INSIG1 | INSIG2 | INSL3 | INSL4 | INSL5 | INSL6 | INSM1 | INSM2 | INSR | INSRR | Insulin-like growth factor | Insulin-like growth factor 2 mRNA binding protein | Insulin-like growth factor 2 mRNA-binding protein 1 (isoform 2) | Insulin-like growth factor-binding protein